Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 4/20 | 0.61 |
| ▸ | MGAT3 | Q09327 | 8/20 | 0.54 |
| ▸ | SCN1A | P35498 | 1/20 | 0.52 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.51 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MGAT2 | Q10469 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.50 |
| ▸ | MGAT1 | P26572 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12783443 | 0.93 | PKM (0.58) | PKMMGAT3SCN1ASCN8APTPN1 | |
| SCHEMBL12782748 | 0.83 | SCN3A (0.70) | PKMSCN1ASCN8APTPN1PTPN11 | |
| SCHEMBL12845646 | 0.81 | SCN3A (0.55) | PKMSCN1ASCN8AALDH1A1MEN1 | |
| SCHEMBL15399931 | 0.81 | CA1 (0.54) | PKMSCN1ASCN8APTPN1PTPN11 | |
| SCHEMBL12845590 | 0.81 | SCN3A (0.71) | PKMSCN1ASCN8AALDH1A1MEN1 | |
| SCHEMBL12845725 | 0.81 | SCN3A (0.59) | PKMSCN1ASCN8AALDH1A1MEN1 | |
| SCHEMBL12845594 | 0.81 | SCN3A (0.57) | PKMALDH1A1MOGAT2SCN3A | |
| SCHEMBL12845826 | 0.79 | SCN3A (0.59) | PKMALDH1A1SCN3A | |
| SCHEMBL2075384 | 0.78 | SCN3A (0.57) | SCN3ASMN1; SMN2 | |
| SCHEMBL12845613 | 0.77 | SCN3A (0.53) | SCN1ASCN8AMOGAT2SCN3ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9035059-B2 | Nitrogen-containing condensed heterocyclic compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-05-19 | — | — | US | claimed |
| EP-2687507-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND | Taisho Pharmaceutical Co., Ltd. (JP) | 2014-01-22 | — | — | EP | claimed |
| US-20140005382-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-01-02 | — | — | US | claimed |
| US-9035059-B2 | Nitrogen-containing condensed heterocyclic compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-05-19 | — | — | US | disclosed |
| EP-2687507-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND | Taisho Pharmaceutical Co., Ltd. (JP) | 2014-01-22 | — | — | EP | disclosed |
| US-20140005382-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-01-02 | — | — | US | disclosed |
| US-8362032-B2 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-29 | — | — | US | disclosed |
| US-20110059965-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-7786137-B2 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786137-B2 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-20090012117-A1 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-01-08 | — | — | US | disclosed |
| US-20090012117-A1 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005382-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND | LCAT, ACAT2, SOAT2 | PKM 3550/4885MGAT3 222/4885SCN1A 1263/4885 |
| US-20090012117-A1 | Bicyclic derivatives as modulators of ion channels | CACNA1C, CACNA1B, CACNA1D | PKM 2958/4885MGAT3 1330/4885SCN1A 54/4885 |
| US-20110059965-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | CACNA1C, CACNA1B, CACNA1D | PKM 2958/4885MGAT3 1330/4885SCN1A 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.